Peripheral Neuropathy Treatment Market Size to grow by USD 447.3 million between 2024-2028
According to a research report “ Peripheral Neuropathy Treatment Market” by Type (Diabetic peripheral neuropathy, Chemotherapy induced peripheral neuropathy, Others) Therapy (Pharmacological therapies, Non pharmacological therapies) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 447.3 million, at a CAGR of 4.36% during the forecast period. The global peripheral neuropathy treatment market is poised for significant expansion due to the rising prevalence of this condition, particularly among individuals with diabetes. Peripheral neuropathy is a category of disorders affecting the peripheral nervous system, encompassing over 100 identified types. Causes encompass trauma, diabetes, vascular issues, systemic autoimmune diseases, hormonal imbalances, kidney and liver disorders, certain malignancies, chemotherapy, and infections. Diabetes, in particular, is a leading etiology, with the CDC estimating a prevalence rate of 6-51% among diabetic adults, contingent on age, diabetes duration, glucose control, and diabetes type..
Browse market data tables, figures, and in-depth TOC on “Peripheral Neuropathy Treatment Market” by Type (Diabetic peripheral neuropathy, Chemotherapy induced peripheral neuropathy, Others) Therapy (Pharmacological therapies, Non pharmacological therapies) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Type, the Diabetic peripheral neuropathy segment is projected to dominate the market size in 2024
The diabetic peripheral neuropathy segment is projected to expand significantly during the forecast period due to the increasing prevalence of diabetes and its associated complications. Diabetic peripheral neuropathy occurs as a result of nerve damage caused by diabetes, leading to a decrease in nerve action potential and impaired neuronal signal transmission. The complex pathogenesis of diabetic peripheral neuropathy involves both metabolic and vascular factors, with hyperglycemia being a key metabolic event contributing to axonal and microvascular injury. This condition significantly increases the risk of foot ulcers in diabetic patients, with other contributing factors including elevated triglycerides, excess body weight, smoking, and high blood pressure.
By Therapy, Pharmacological therapies segment is expected to hold the largest market size for the year 2024
Diabetic peripheral neuropathy (DPN), the most prevalent complication of diabetes, affects approximately 50% of diabetic adults throughout their lifetime. This condition, which accounts for 75% of diabetic neuropathy instances, necessitates effective treatment strategies. Pharmacological interventions are typically recommended for managing DPN-related pain. First-line treatments include anticonvulsants, such as pregabalin and gabapentin, which have shown significant efficacy. Second- and third-line therapies may involve topical agents, including capsaicin and isosorbide dinitrate. Opioids and related drugs are recommended for short-term pain relief during acute exacerbations. Combination therapies may be beneficial for patients who do not respond to monotherapy, ensuring optimal pain management in DPN.
North America is forecasted to hold the largest market size by region in 2024
The Peripheral Neuropathy Treatment Market represents a significant business opportunity due to the rising prevalence of diabetes and other neurological disorders. This market is poised for growth as effective treatments for peripheral neuropathy, such as analgesics, antidepressants, and antiepileptics, continue to gain approval. Additionally, emerging therapies like gene therapy and stem cell treatment offer promising avenues for innovation. Market players must stay abreast of regulatory developments and consumer trends to capitalize on this expanding market.
The Peripheral Neuropathy Treatment Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Title: Peripheral Neuropathy Treatment Market: Hospital Pharmacy, Specialty Clinics, Homecare, and Beyond Peripheral neuropathy, a condition characterized by damage to the peripheral nerves, affects millions globally. The treatment market for peripheral neuropathy is diverse and expanding, catering to various patient populations and administration routes. Hospital pharmacies offer parenteral administration of immunoglobulins and intravenous pain relievers for severe cases. Specialty clinics provide personalized care for patients with underlying conditions like cancers, liver or kidney disorders, hormonal imbalance, autoimmune diseases, trauma, or physical injury. Homecare services offer oral medications such as anti-seizure drugs, pain relievers, and physical therapy for managing symptoms. Immunoglobulins and other injectable treatments are also available for home administration. The obese and geriatric populations, common demographics for peripheral neuropathy, benefit from these treatment modalities. Symptoms like urination, digestion issues, pain, numbness, weakness in feet and hands, and spinal cord or brain involvement call for various therapeutic interventions. Treatment for peripheral neuropathy continues to evolve, addressing the diverse needs of patients with this complex condition.
Market Research Overview
Peripheral neuropathy is a disorder affecting the peripheral nervous system, characterized by symptoms such as pain, numbness, weakness, and muscle atrophy in the hands and feet. The epidemiology of peripheral neuropathy is vast, with various causes including hereditary disorders, toxic exposures, systemic diseases, and chemotherapy treatments. Adherence rates to treatment plans can be low due to side-effects, such as pain, nausea, and fatigue, associated with some medications like chemotherapy drugs and anti-seizure medications. Mortality rates for peripheral neuropathy depend on the underlying cause, with life-threatening disorders like cancer and diabetes mellitus leading to significant mortality. Treatment options include medications like immunoglobulins, physical therapy, and pain relievers, as well as non-pharmacological therapies like physiotherapy and radiotherapy. Retail pharmacies, online pharmacies, hospital pharmacies, specialty clinics, homecare, parenteral, and oral drug formulations are common channels for accessing peripheral neuropathy treatments. Some innovative treatments in the pipeline include gene therapy and plasmid DNA therapy. Central nervous system disorders, peripheral arterial diseases, chronic wounds, muscle diseases, neuromuscular diseases, neurodegenerative disorders, ischemic diseases, and paclitaxel-induced peripheral neuropathy are some conditions associated with peripheral neuropathy. Causes range from infections and benign tumors to cancers, liver and kidney disorders, hormonal imbalance, autoimmune diseases, trauma, and physical injury. Clinical assessment, nerve biopsy, electro diagnostic studies, and laboratory testing are essential for diagnosing peripheral neuropathy. Treatment may also involve addressing underlying causes, such as nutritional deficiencies, circulation issues, and urination and digestion problems. Non-pharmacological therapies like acupuncture and transcutaneous electrical nerve stimulation can also be effective. Idiopathic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and diabetic peripheral neuropathy are common types of peripheral neuropathy. Memantine and venlafaxine are some medications used to manage symptoms. Clinical trials are ongoing to explore new treatments and improve existing ones. In summary, peripheral neuropathy is a complex disorder with various causes and treatments. Adherence to treatment plans can be challenging due to side-effects, but innovative treatments and delivery channels offer hope for better management and improved outcomes.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
